KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medtronic (MDT) EBITDA (2016 - 2025)

Historic EBITDA for Medtronic (MDT) over the last 12 years, with Q4 2025 value amounting to $1.7 billion.

  • Medtronic's EBITDA rose 570.53% to $1.7 billion in Q4 2025 from the same period last year, while for Oct 2025 it was $6.2 billion, marking a year-over-year increase of 1486.41%. This contributed to the annual value of $6.0 billion for FY2025, which is 1576.59% up from last year.
  • Medtronic's EBITDA amounted to $1.7 billion in Q4 2025, which was up 570.53% from $1.4 billion recorded in Q3 2025.
  • In the past 5 years, Medtronic's EBITDA registered a high of $1.7 billion during Q4 2025, and its lowest value of $859.0 million during Q3 2021.
  • Over the past 5 years, Medtronic's median EBITDA value was $1.4 billion (recorded in 2025), while the average stood at $1.4 billion.
  • Per our database at Business Quant, Medtronic's EBITDA soared by 40791.14% in 2021 and then plummeted by 3271.57% in 2024.
  • Over the past 5 years, Medtronic's EBITDA (Quarter) stood at $1.6 billion in 2021, then dropped by 10.17% to $1.4 billion in 2022, then decreased by 4.56% to $1.3 billion in 2023, then grew by 19.03% to $1.6 billion in 2024, then grew by 5.71% to $1.7 billion in 2025.
  • Its EBITDA stands at $1.7 billion for Q4 2025, versus $1.4 billion for Q3 2025 and $1.4 billion for Q2 2025.